Kathleen Knights

2.8k citations
55 papers · 2.2k · h-index 27

Impact in

  • Pharmacology top 0.1%
    • Pharmacogenetics and Drug Metabolism
    • Drug-Induced Hepatotoxicity and Protection
    • Inflammatory mediators and NSAID effects
  • Clinical Biochemistry top 2%
    • Metabolism and Genetic Disorders

Papers in

  • Pharmacology 30
    • Pharmacogenetics and Drug Metabolism 29
    • Inflammatory mediators and NSAID effects 9
    • Drug-Induced Hepatotoxicity and Protection 9
  • Molecular Biology 18
    • Peroxisome Proliferator-Activated Receptors 6
Co-authors
John O. Miners (29 shared papers)Peter I. Mackenzie (11 shared papers)Andrew Rowland (10 shared papers)David J. Elliot (7 shared papers)Kushari Bowalgaha (5 shared papers)Arduino A. Mangoni (6 shared papers)Benedetta C. Sallustio (5 shared papers)J. Brian Houston (1 shared paper)
Journals
Biochemical Pharmacology (16 papers)Drug Metabolism and Disposition (7 papers)British Journal of Clinical Pharmacology (6 papers)Drug Metabolism Reviews (3 papers)Expert Opinion on Drug Metabolism & Toxicology (2 papers)
Partner nations
AustraliaUnited KingdomThailand

In The Last Decade

Kathleen Knights

55 papers receiving 2.2k citations

Peers

Kathleen Knights
Comparison fields: 5 of 99
  • Pharmacology 1.2k
  • Clinical Biochemistry 195
  • Oncology 680
  • Biochemistry 169
  • Pharmacology 357
Replace Robin E. Pearce with:
Robin E. Pearce United States
P. Kremers Belgium
Véronique Descatoire France
Miki Katoh Japan
Mikael Oscarson Sweden
G. M. Pacifici Italy
A. David Rodrigues United States
A. David Rodrigues United States
J. Andrew Williams United States
Alain Berson France
Kathleen Knights relative to Robin E. Pearce United States Robin E. Pearce's profile →
Citations per field
00.5×1.6×
Robin E. Pearce · 1×
Citations per year

Countries citing papers authored by Kathleen Knights

Since Specialization
Citations

This map shows the geographic impact of Kathleen Knights's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kathleen Knights with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kathleen Knights more than expected).

Fields of papers citing papers by Kathleen Knights

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kathleen Knights. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kathleen Knights. The network helps show where Kathleen Knights may publish in the future.

Co-authors

The 25 scholars most cited alongside Kathleen Knights, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kathleen Knights Line = papers co-authored together Kathleen Knights links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 55 papers — load more, or switch the sort, to bring in the rest.

#Work
1
The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping andin vitro–in vivoextrapolation of drug clearance and drug-drug interaction potential
Drug Metabolism Reviews ·John O. Miners, Peter I. Mackenzie, Kathleen Knights
2009185
2
In vitro–in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: Pitfalls and promises
Biochemical Pharmacology ·John O. Miners, Kathleen Knights, J. Brian Houston, Peter I. Mackenzie
2006168
3
Renal drug metabolism in humans: the potential for drug–endobiotic interactions involving cytochrome P450 (CYP) andUDP‐glucuronosyltransferase (UGT)
British Journal of Clinical Pharmacology ·Kathleen Knights, Andrew Rowland, John O. Miners
2013167
4
The “Albumin Effect” and Drug Glucuronidation: Bovine Serum Albumin and Fatty Acid-Free Human Serum Albumin Enhance the Glucuronidation of UDP-Glucuronosyltransferase (UGT) 1A9 Substrates but Not UGT1A1 and UGT1A6 Activities
Drug Metabolism and Disposition ·Andrew Rowland, Kathleen Knights, Peter I. Mackenzie, John O. Miners
2008137
5
Binding of Inhibitory Fatty Acids Is Responsible for the Enhancement of UDP-Glucuronosyltransferase 2B7 Activity by Albumin: Implications for in Vitro-in Vivo Extrapolation
Journal of Pharmacology and Experimental Therapeutics ·Andrew Rowland, Voula Gaganis, David J. Elliot, Peter I. Mackenzie, Kathleen Knights, John O. Miners
2007134
6
Characterization of Niflumic Acid as a Selective Inhibitor of Human Liver Microsomal UDP-Glucuronosyltransferase 1A9: Application to the Reaction Phenotyping of Acetaminophen Glucuronidation
Drug Metabolism and Disposition ·John O. Miners, Kushari Bowalgaha, David J. Elliot, Paweł Baranczewski, Kathleen Knights
201195
7
S‐Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP‐glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen
British Journal of Clinical Pharmacology ·Kushari Bowalgaha, David J. Elliot, Peter I. Mackenzie, Kathleen Knights, Stellan Swedmark, John O. Miners
200589
8
Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity
Expert Review of Clinical Pharmacology ·Kathleen Knights, Arduino A. Mangoni, John O. Miners
201089
9
Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7
Biochemical Pharmacology ·Paraskevi Tsoutsikos, John O. Miners, Alan M. F. Stapleton, Anthony J. Thomas, Benedetta C. Sallustio, Kathleen Knights
200374
10
Amino acid conjugation: contribution to the metabolism and toxicity of xenobiotic carboxylic acids
Expert Opinion on Drug Metabolism & Toxicology ·Kathleen Knights, Matthew J. Sykes, John O. Miners
200772
11
Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia
Biochemical Pharmacology ·John O. Miners, Nuy Chau, Andrew Rowland, Kushari Burns, Ross A. McKinnon, Peter I. Mackenzie, Geoffrey T. Tucker, Kathleen Knights, Ganessan Kichenadasse
201771
12
The “Albumin Effect” and in Vitro-in Vivo Extrapolation: Sequestration of Long-Chain Unsaturated Fatty Acids Enhances Phenytoin Hydroxylation by Human Liver Microsomal and Recombinant Cytochrome P450 2C9
Drug Metabolism and Disposition ·Andrew Rowland, David J. Elliot, Kathleen Knights, Peter I. Mackenzie, John O. Miners
200871
13
The stereospecific incorporation of fenoprofen into rat hepatocyte and adipocyte triacylglycerols
Biochemical Pharmacology ·Benedetta C. Sallustio, Peter J. Meffin, Kathleen Knights
198857
14
Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP‐glucuronosyltransferases: Inhibition by NSAIDs
British Journal of Clinical Pharmacology ·Kathleen Knights, Leanne K. Winner, David J. Elliot, Kushari Bowalgaha, John O. Miners
200955
15
Glucuronidation of fenamates: Kinetic studies using human kidney cortical microsomes and recombinant UDP-glucuronosyltransferase (UGT) 1A9 and 2B7
Biochemical Pharmacology ·Voula Gaganis, John O. Miners, Kathleen Knights
200751
16
In vitro characterisation of human renal and hepatic frusemide glucuronidation and identification of the UDP-glucuronosyltransferase enzymes involved in this pathway
Biochemical Pharmacology ·Oranun Kerdpin, Kathleen Knights, David J. Elliot, John O. Miners
200848
17
ROLE OF HEPATIC FATTY ACID:COENZYME A LIGASES IN THE METABOLISM OF XENOBIOTIC CARBOXYLIC ACIDS
Clinical and Experimental Pharmacology and Physiology ·Kathleen Knights
199846
18
Scaling factors for thein vitro–in vivoextrapolation (IV–IVE) of renal drug and xenobiotic glucuronidation clearance
British Journal of Clinical Pharmacology ·Kathleen Knights, Shane M. Spencer, John K. Fallon, Nuy Chau, Philip C. Smith, John O. Miners
201641
19
Use of non‐steroidal anti‐inflammatory drugs and risk of incident myocardial infarction and heart failure, and all‐cause mortality in the Australian veteran community
British Journal of Clinical Pharmacology ·Arduino A. Mangoni, Richard Woodman, Voula Gaganis, Andrew L. Gilbert, Kathleen Knights
201036
20
Effect of Albumin on Human Liver Microsomal and Recombinant CYP1A2 Activities: Impact on In Vitro-In Vivo Extrapolation of Drug Clearance
Drug Metabolism and Disposition ·Nitsupa Wattanachai, Wichittra Tassaneeyakul, Andrew Rowland, David J. Elliot, Kushari Bowalgaha, Kathleen Knights, John O. Miners
201235

About Kathleen Knights

Kathleen Knights is a scholar working on Pharmacology, Molecular Biology, Biochemistry, Oncology and Pharmacology, having authored 55 papers that have together received 2.2k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (29 papers), Eicosanoids and Hypertension Pharmacology (13 papers), Drug Transport and Resistance Mechanisms (12 papers), Metabolism and Genetic Disorders (9 papers), Inflammatory mediators and NSAID effects (9 papers), Drug-Induced Hepatotoxicity and Protection (9 papers), Peroxisome Proliferator-Activated Receptors (6 papers) and Alcohol Consumption and Health Effects (5 papers). The work is most often cited by research in Pharmacology (1.2k citations), Clinical Biochemistry (195 citations), Oncology (680 citations), Biochemistry (169 citations) and Pharmacology (357 citations). Kathleen Knights has collaborated with scholars based in Australia, United Kingdom and Thailand. Frequent co-authors include John O. Miners, Peter I. Mackenzie, Andrew Rowland, David J. Elliot, Kushari Bowalgaha, Arduino A. Mangoni, Benedetta C. Sallustio, J. Brian Houston, Matthew J. Sykes and Peter J. Meffin. Their work appears in journals such as Biochemical Pharmacology, Drug Metabolism and Disposition, British Journal of Clinical Pharmacology, Drug Metabolism Reviews and Expert Opinion on Drug Metabolism & Toxicology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robin E. PearceBreakdown of academic impact, for papers by P. KremersBreakdown of academic impact, for papers by Véronique DescatoireBreakdown of academic impact, for papers by Miki KatohBreakdown of academic impact, for papers by Mikael OscarsonBreakdown of academic impact, for papers by G. M. PacificiBreakdown of academic impact, for papers by A. David RodriguesBreakdown of academic impact, for papers by A. David RodriguesBreakdown of academic impact, for papers by J. Andrew WilliamsBreakdown of academic impact, for papers by Alain Berson